TRAW Key Statistics, Chart & Performance
The current stock price of TRAW is 1.61 USD. In the past month the price decreased by -30.9%. In the past year, price decreased by -73.82%.
TRAW Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.99 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.58 | 514.75B | ||
| MRK | MERCK & CO. INC. | 12.29 | 268.70B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.84B | ||
| ZTS | ZOETIS INC | 19.66 | 54.92B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.82 | 23.30B | ||
| VTRS | VIATRIS INC | 5.74 | 15.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.47 | 12.15B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.79B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.48B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.15B |
Related stock screener links
About TRAW
Company Profile
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Company Info
TRAWS PHARMA INC
12 Penns Trail
Newtown PENNSYLVANIA US
Employees: 7
Phone: 12677593680
TRAWS PHARMA INC / TRAW FAQ
What does TRAW do?
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
What is the current price of TRAW stock?
The current stock price of TRAW is 1.61 USD. The price increased by 26.77% in the last trading session.
Does TRAWS PHARMA INC pay dividends?
TRAW does not pay a dividend.
What is the ChartMill rating of TRAWS PHARMA INC stock?
TRAW has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists TRAW stock?
TRAW stock is listed on the Nasdaq exchange.
What is TRAWS PHARMA INC worth?
TRAWS PHARMA INC (TRAW) has a market capitalization of 12.86M USD. This makes TRAW a Nano Cap stock.
TRAW Technical Analysis
TRAW Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TRAW. The financial health of TRAW is average, but there are quite some concerns on its profitability.
TRAW Financial Highlights
Over the last trailing twelve months TRAW reported a non-GAAP Earnings per Share(EPS) of 28.26. The EPS increased by 119.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3279.34% | ||
| ROA | 777.75% | ||
| ROE | 2051.21% | ||
| Debt/Equity | 0 |
TRAW Forecast & Estimates
7 analysts have analysed TRAW and the average price target is 8.16 USD. This implies a price increase of 406.83% is expected in the next year compared to the current price of 1.61.
For the next year, analysts expect an EPS growth of 99.97% and a revenue growth 1117.39% for TRAW